• 1
    Progress in hepatitis B prevention through universal infant vaccination—China, 1997–2006. MMWR Morb Mortal Wkly Rep 2007; 56: 441445.
  • 2
    World Health Organization. WHO report 2008. Global tuberculosis control—surveillance, planning, financing. Available at: Accessed November 18, 2008.
  • 3
    World Health Organization. Epidemiological fact sheet on HIV and AIDS: China. Available at: Accessed November 18, 2008.
  • 4
    World Health Organization. WHO Disease and injury country estimates. Available at: Accessed October 30, 2008.
  • 5
    World Health Organization. Malaria annual data. Available at: Accessed November 18, 2008.
  • 6
    Liu J, Fan D. Hepatitis B in China. Lancet 2007; 369: 15821583.
  • 7
    Sun Z, Ming L, Zhu X, Lu J. Prevention and control of hepatitis B in China. J Med Virol 2002; 67: 447450.
  • 8
    The Ministry of Health conference on planning and hepatitis B immunization, malaria prevention and control work [in Chinese]. Available at: Accessed August 1, 2008.
  • 9
    United States Census Bureau. China International Database country summary. Available at: Accessed November 18, 2008.
  • 10
    Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10: 751774.
  • 11
    Wittet S. Hepatitis B Vaccine Introduction—Lessons Learned in Advocacy, Communication, and Training. Seattle, Washington: Program for Appropriate Technology in Health (PATH), Bill and Melinda Gates Children's Vaccine Program, 2001. Bill and Melinda Gates Children's Vaccine Program Occasional Paper No. 4.
  • 12
    World Health Organization. Western Pacific Regional Plan for Hepatitis B Control Through Immunization. Manila, Philippines: World Health Organization; 2007. Report No. (WP)/ICP/EPI/5.2/001-E.
  • 13
    Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821831.
  • 14
    Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147: 460469.
  • 15
    Murray CJ, Lopez A. World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization, 2002.
  • 16
    International Monetary Fund. World Economic Outlook Database for October 2007 October 17, 2007.
  • 17
  • 18
    Central Intelligence Agency. The World Factbook—China. Available at: Accessed August 1, 2008.
  • 19
    Murray CJL, Salomon JA, Mathers CD, Lopez AD, editors. Summary Measures of Population Health. Concepts, Ethics, Measurement and Applications. Geneva, Switzerland: World Health Organization, 2002.
  • 20
    Gong XH, Li YH, Liu LR, Jia L, Xing YL, Wang YQ. Study on the afficacy [sic] of hepatitis B immunization among youngsters in Beijing [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 388390.
  • 21
    Gong XH, Liu LR, Jia L, Li YH, Xing YL, Wang QY. Epidemiological effect of hepatitis B immunization among newborn babies in Beijing [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 201202.
  • 22
    Zhiqiang G, Zhaohui D, Qinhuan W, Dexian C, Yunyun F, Hongtao L, Iloeje UH. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004; 38 (Suppl.): S175S178.
  • 23
    World Health Organization. Hepatitis B. Fact sheet no. 204. Geneva, Switzerland: World Health Organization, 2008.
  • 24
    Shivananda, Somani V, Srikanth BS, Mohan M, Kulkarni PS. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India. Clin Vaccine Immunol 2006; 13: 661664.
  • 25
    Alimonos KK, Nafziger AAN, Murray JJ, Bertino JJS. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin Infect Dis 1998; 26: 566571.
  • 26
    Chen JJ. A model HBV catch-up immunization and education project in Qinghai, China. In: National Immunization Conference 2008. March 17, 2008.
  • 27
    People's Daily Online. Chinese, U.S. agencies help hepatitis B prevention in northwest China. Available at: Accessed November 18, 2008.
  • 28
    Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, Lin CY, et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2005; 26: 655658.
  • 29
    Li RC, Yang JY, Gong J, Li YP, Huang ZN, Fang KX, et al. Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 385387.
  • 30
    Gong J, Li RC, Yang JY, Li YP, Chen XR, Xu ZY, et al. Long-term efficacy of infant hepatitis B immunization program [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 203205.
  • 31
    Margolis H, Coleman P, Brown R, Mast E, Sheingold S, Arevalo J. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995; 274: 12011208.
  • 32
    Pisu M, Meltzer M, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 2002; 21: 312321.
  • 33
    Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993; 253: 197201.
  • 34
    Seeff L, Beebe G, Hoofnagle J, Norman J, Buskell-Bales Z, Waggoner J, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. New Engl J Med 1987; 316: 965970.
  • 35
    Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 36
    Chen D, Yao G-b, Chen W. Economic evaluation of peginterferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B [in Chinese]. Chinese Hepatology 2007; 12: 164167.
  • 37
    Jacobs R, Saab S, Meyerhoff A. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 2003; 51: 227236.
  • 38
    Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1200.
  • 39
    Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Organ 2003; 81: 334342.
  • 40
    Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192: 17201726.
  • 41
    Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192 (Suppl. 1): S133S145.
  • 42
    Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93: 5258.
  • 43
    Dai ZC, Qi GM. Viral Hepatitis in China: Seroepidemiological Survey in Chinese Population (Part One) 1992–1995. Beijing, China: Scientific and Technical Documents Publishing House, 1997.
  • 44
    State Statistical Bureau of the People's Republic of China. China Statistical Yearbook. English ed. Hong Kong: International Centre for the Advancement of Science & Technology, 2006.
  • 45
    Bristol-Myers Squibb Foundation and China Foundation for Hepatitis Prevention and Control collaborate to fight one of China's most pressing health problems. Available at: Accessed November 1, 2008.
  • 46
    Ho L. Public “lacks awareness” of hepatitis B. Available at: Accessed November 1, 2008.
  • 47
    Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the “healthy” HBsAg carrier state. HEPATOLOGY 1987; 7: 758763.
  • 48
    McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599603.
  • 49
    Lin X, Robinson NJ, Thursz M, Rosenberg DM, Weild A, Pimenta JM, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 2005; 20: 833843.
  • 50
    Centers for Disease Control and Prevention (CDC). Hepatitis B fact sheet. Available at: Accessed April 8, 2008.
  • 51
    Chen CJ, Yang HI, Su JUN, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 52
    Perrillo R, Hann H, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 53
    Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 54
    Chan HL-Y, Leung NW-Y, Hui AY, Wong VW-S, Liew C-T, Chim AM-L, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-{alpha}2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240250.
  • 55
    Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004; 24: 4553.
  • 56
    Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 1998; 5: 389397.
  • 57
    Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 21322137.
  • 58
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-{alpha}2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855865.
  • 59
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 15621569.
  • 60
    Organ Procurement and Transplantation Network. Data. Available at: Accessed November 1, 2008.
  • 61
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228237.
  • 62
    Yuen M-F, Cheng C-C, Lauder IJ, Lam S-K, Ooi CG, Lai C-L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. HEPATOLOGY 2000; 31: 330335.
  • 63
    Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2005; 2006: 801807.
  • 64
    Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th ed. Washington, DC: Public Health Foundation, 2007.
  • 65
    Hu RH, Ho MC, Wu YM, Yu SC, Lee PH. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin Transplant 2005; 19: 175180.
  • 66
    Pierie JP, Muzikansky A, Tanabe KK, Ott MJ. The outcome of surgical resection versus assignment to the liver transplant waiting list for hepatocellular carcinoma. Ann Surg Oncol 2005; 12: 552560.
  • 67
    Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, et al. Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience. Transplant Proc 2007; 39: 153159.
  • 68
    Clements CJ, Baoping Y, Crouch A, Hipgrave D, Mansoor O, Nelson CB, et al. Progress in the control of hepatitis B infection in the Western Pacific region. Vaccine 2006; 24: 19751982.
  • 69
    Juan S. China “has 120m hepatitis B carriers.” Available at: Accessed November 1, 2008.
  • 70
    UNICEF. 2003 Vaccine projection: quantities and pricing. Available at: Accessed November 18, 2008.
  • 71
    Li SC, Ong SC, Lim SG, Yeoh KG, Kwong KS, Lee V, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004; 38: S136S143.
  • 72
    Lacey L, Tan A. Economic evaluation of different treatments of HBeAg-negative chronic hepatitis B in China [in Chinese]. Chin J Infect Dis 2007; 25: 473479.